Instil Bio
39 hedge funds and large institutions have $100M invested in Instil Bio in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 3 reducing their positions, and 18 closing their positions.
533% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 3
1.61% less ownership
Funds ownership: 81.82% → 80.21% (-1.6%)
20% less funds holding
Funds holding: 49 → 39 (-10)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
72% less capital invested
Capital invested by funds: $358M → $100M (-$258M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.87M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.77M |
| 3 |
O
OrbiMed
New York
|
+$2.53M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.98M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$23.3M |
| 2 |
CC
Commodore Capital
New York
|
-$10.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$9.77M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.43M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.96M |
TIL Hedge Fund Activity: Q4 2024 in Review
39 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q4 2024, worth a combined $100M — down 72% from $358M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TIL and 8 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 19 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $3.87M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $23.3M sold.
- 39 institutional investors held Instil Bio (TIL) as of Q4 2024, down from 49 in Q3 2024.
- Funds reported $100M of Instil Bio stock for Q4 2024, down 72% quarter-over-quarter.
- 8 funds opened new Instil Bio positions in Q4 2024 and 18 closed out, a net change of -10 holders.
- The largest Instil Bio buyer in Q4 2024 was Goldman Sachs, an estimated $3.87M added.
- The largest Instil Bio seller in Q4 2024 was Perceptive Advisors, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2024.